NeuroSense Therapeutics Management
Management criteria checks 1/4
NeuroSense Therapeutics' CEO is Alon Ben-Noon, appointed in Jan 2016, has a tenure of 8.33 years. total yearly compensation is $1.57M, comprised of 26.1% salary and 73.9% bonuses, including company stock and options. directly owns 17.78% of the company’s shares, worth $4.10M. The average tenure of the management team and the board of directors is 2.3 years and 2.4 years respectively.
Key information
Alon Ben-Noon
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 26.1% |
| CEO tenure | 8.3yrs |
| CEO ownership | 17.8% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$11m |
| Sep 30 2023 | n/a | n/a | -US$11m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$2m | US$410k | -US$12m |
Compensation vs Market: Alon's total compensation ($USD1.57M) is above average for companies of similar size in the US market ($USD667.96K).
Compensation vs Earnings: Insufficient data to compare Alon's compensation with company performance.
CEO
Alon Ben-Noon (44 yo)
8.3yrs
Tenure
US$1,568,000
Compensation
Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 2.9yrs | US$1.02m | 2.65% $ 611.8k | |
| Chief Medical Officer | 2.4yrs | US$918.00k | 0.71% $ 163.5k | |
| Co-Founder | 8.3yrs | US$1.57m | 17.78% $ 4.1m | |
| Chief Operation Officer | no data | no data | 0.13% $ 29.3k | |
| Chief Technology Officer | less than a year | no data | 0.38% $ 87.0k | |
| VP of Quality & Compliance | 2.3yrs | no data | no data | |
| Head of HR | less than a year | no data | no data | |
| C.R.A. | 1.3yrs | no data | no data |
2.3yrs
Average Tenure
44.5yo
Average Age
Experienced Management: NRSN's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.3yrs | US$1.57m | 17.78% $ 4.1m | |
| Independent Chairman of the Board | 2.6yrs | US$1.48m | 0.37% $ 85.1k | |
| Independent External Director | 2.4yrs | US$104.00k | 0.14% $ 31.9k | |
| Independent External Director | 2.4yrs | US$104.00k | 0.14% $ 31.9k | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Director | 2.3yrs | US$91.00k | 0.16% $ 37.9k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 2.4yrs | US$176.00k | 0.14% $ 31.9k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data |
2.4yrs
Average Tenure
57yo
Average Age
Experienced Board: NRSN's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.